Special Drug Use-results Surveillance of Tafinlar/Mekinist
This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture.
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
DRUG: Tafinlar/Mekinist
[Pediatric patients] Number of patients and incidence of adverse events/adverse reactions with respect to skeletal and sexual maturation, To evaluate impairment in growth and development in pediatric patients (skeletal and sexual maturation) of dabrafenib and/or trametinib in pediatric patients under 18 years old in the post marketing phase., Up to 8 years|[Adult patients] overall response rate (ORR), The Overall Response Rate (ORR) is defined as the proportion of patients with a best OR of confirmed Complete Response (CR) or Partial Response (PR), 1 year
[Pediatric patients] Incidence proportion of ORR, The Overall Response Rate (ORR) is defined as the proportion of patients with a best OR of confirmed Complete Response (CR) or Partial Response (PR), 1 year|[Pediatric and adult patients] Incidence proportion of PFS, Progression Free Survival (PFS) is the percentage of participants who did not have a progression event., 1 year|[Pediatric patients] Number of patients with changes in height and body weight and sexual maturation, Number of pediatric patients with changes in height and body weight and sexual maturation is going to be collected, Up to 8 years
In the Post-Marketing Surveillance (PMS), dabrafenib and trametinib are used as the marketed drugs. Registration of the corresponding patients is to be conducted by the central registered system under current medical practice.

Target number of adult patient is 65 (as the number of patients in the effectiveness analysis set).

Target number of pediatric patient is not determined. Estimated number of enrolled patients is approximately 20 (as the number of patients in the enrolled set)

The observation period for pediatric patients will last after the start of treatment until 8 years (planned, November 2031) after the approval of additional indications, regardless of discontinuation of the product, in order to collect long-term information from as many patients as possible during the reexamination period. The duration of observation for adult patients will be 1 year after the start of treatment with the product.